Transfusion of Pathogen Reduced Cryoprecipitated Fibrinogen to Expedite

Status Recruiting

Clinical Trial Summary

The goal of this quality improvement study is to compare pathogen-reduced cryoprecipitate with traditional cryoprecipitate in liver transplant and cardiovascular patients. The investigators hypothesize that by having immediate access to a readily available thawed blood product that replaces fibrinogen (the main substrate of a blood clot), early bleeding can be treated before it escalates into uncontrolled hemorrhage, and therefore additional blood products, like platelets, plasma and red blood cells can be avoided. Participants will be given one of the two FDA-approved blood products.

Clinical Trial Description

Immediately replacing fibrinogen in perioperative bleeding patients with acquired fibrinogen deficiency improves outcomes. The product that is primarily used for fibrinogen replacement in the US, cryoprecipitate (cryo), must be stored frozen and expires six hours after thawing, resulting in a delay in transfusion of approximately 50 minutes from the time it is ordered, as well as unnecessary transfusion of more readily available but not indicated blood components that are transfused while the patients waits for cryo . A modified version of the product, pathogen reduced (PR) cryo, is now FDA approved and can be thawed and stored for 5 days, allowing the product to be available immediately when needed. In this quality improvement study, the investigators will compare the effect that readily available, pre-thawed PR cryo has on transfusion practice in cardiovascular and liver transplant patients who receive PR cryo versus those who receive traditional cryo by randomizing cryo transfusions in the blood bank by month to all cryo or all PR cryo. All clinical decisions, including the need for cryo, and laboratory testing will occur per standard of care. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT05711524
Study type	Interventional
Source	Weill Medical College of Cornell University
Contact	Melissa Cushing
Phone	212-746-3527
Email	mec2013@med.cornell.edu
Status	Recruiting
Phase	Phase 4
Start date	April 1, 2023
Completion date	March 2025

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT04058223` - Comparison of the Short-term Outcomes of Using DST and PPH Staplers in the Treatment of Grade III and IV Hemorrhoids
Completed	`NCT03678168` - A Comparison Between Conventional Throat Packs and Pharyngeal Placement of Tampons in Rhinology Surgeries	N/A
Completed	`NCT05669313` - The Effects of Hypothermia and Acidosis on Coagulation During Treatment With Rivaroxaban Measured With ROTEM
Completed	`NCT04590898` - Peri-device Leakage Closure After LAAO
Active, not recruiting	`NCT05563883` - Atrial Fibrillation and Cancer: a Nationwide French Cohort Study
Not yet recruiting	`NCT04537533` - Tranexamic Acid Infusion in Low Dose Versus in High Dose for Reducing Blood Loss in Radical Cystectomy Operations	Phase 4
Withdrawn	`NCT02851940` - Pain and Bleeding Following Hypertonic Saline Sclerotherapy Compared to Brand Ligation for Symptomatic Hemorrhoids	N/A
Completed	`NCT02722720` - Carotid Arteries Stenting Complications: Transradial Approach Versus Transfemoral	N/A
Recruiting	`NCT02279186` - Effectiveness of Intravenous Tranexamic Acid in Reducing Blood Loss During and After Cesarean Section	Phase 4
Active, not recruiting	`NCT02244853` - Heart Rate and Cardiovascular Diseases Prognosis in People With Stable Coronary Artery Disease	N/A
Completed	`NCT02092415` - Assessment of Limb Perfusion During Junctional Tourniquet	N/A
Completed	`NCT02245854` - Efficacy and Safety of a New Polypectomy Snare for Cold-polypectomy for Small Colorectal Polyps	N/A
Completed	`NCT02980497` - Antiplaque/Antigingivitis Efficacy of Essential Oil Mouthrinses in Six-Month Study	N/A
Not yet recruiting	`NCT01438736` - Is Cerazette Use Before Nexplanon Insertion Predictive for Bleeding Pattern?	Phase 4
Completed	`NCT00515541` - Lovaza's Effect on the Activation of Platelets	Phase 2
Completed	`NCT00143715` - Oral Vitamin K for Warfarin Associated Coagulopathy	Phase 3
Terminated	`NCT03954314` - DEPOSITION - Decreasing Postoperative Blood Loss by Topical vs. Intravenous Tranexamic Acid in Open Cardiac Surgery	Phase 3
Recruiting	`NCT05945680` - Tranexamic Acid in Breast Esthetic Surgery.	Phase 4
Recruiting	`NCT03783182` - Betamethasone (Betapred®) as Premedication for Reducing Postoperative Vomiting and Pain After Tonsillectomy	Phase 4
Not yet recruiting	`NCT05464394` - Peroperative Administration of Tranexamic Acid in Roux-en-Y Gastric Bypass and One-anastomosis Gastric Bypass	Phase 3

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Transfusion of Pathogen Reduced Cryoprecipitated Fibrinogen to Expedite Product Availability in Perioperative Bleeding

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms